Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2016-07-05 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
FORM OF PROXY
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for use by shareholders at the Annual General Meeting (AGM) of Uni-Bio Science Group Limited. It includes instructions for appointing a proxy to vote on various resolutions at the AGM, such as adopting the audited financial statements, re-electing directors, appointing auditors, and granting mandates related to shares. The document is not the AGM presentation or materials themselves, nor is it the voting results announcement. It is a proxy solicitation document sent to shareholders to enable them to vote at the AGM. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 6426 characters, which is consistent with a detailed proxy form rather than a brief announcement or full report.
2016-07-05 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and contains detailed agenda items for the AGM of Uni-Bio Science Group Limited, including adoption of audited financial statements, re-election of directors, re-appointment of auditors, and approval of share allotment and purchase mandates. It is a formal notice announcing the meeting and the business to be transacted, not the actual report or minutes of the meeting. The document is over 12,000 characters, indicating it is a full notice rather than a brief announcement. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices of meeting and agenda.
2016-07-05 English
GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular from the board of Uni-Bio Science Group Limited dated 6 July 2016. It contains detailed information about the upcoming Annual General Meeting (AGM) scheduled for 5 August 2016, including the grant of general mandates to issue and repurchase shares, re-election of directors, and the notice of the AGM itself. The document includes explanatory statements, biographical details of directors proposed for re-election, and proxy voting instructions. It is not a full annual report or financial statement but rather a comprehensive meeting circular with resolutions and notices related to the AGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length (15,000 characters) and content confirm it is not a brief announcement or proxy solicitation only, but a full circular for the AGM.
2016-07-05 English
Annual Report 2015
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2015/16' and contains detailed sections typical of an annual report, including Corporate Profile, Key Financial Highlights, Chairman's Statement, Management Discussion and Analysis, Profile of Directors and Senior Management, Corporate Governance Report, Directors' Report, Independent Auditor's Report, and full Consolidated Financial Statements with Notes. The content includes comprehensive financial data, business strategy, operational results, and outlook for the year ended 31 December 2015. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics align with the definition of an Annual Report (10-K). FY 2015
2016-07-05 English
PROPOSED ISSUE OF SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed issue of shares under a general mandate, detailing the subscription agreement, subscription price, number of shares, conditions precedent, and the intended use of proceeds. It includes information about the shareholding structure before and after the subscription and references the general mandate granted at the AGM. The document does not contain financial statements or detailed financial performance data but focuses on the capital raising activity and share issuance. It is not a full financial report, earnings release, or management discussion. The content aligns with an update on company fundraising and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence classification.
2016-06-27 English
VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION WITH CHINA RESOURCES ZIZHU FOR GENESOFT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Uni-Bio Science Group Limited regarding a strategic cooperation agreement with China Resources Zizhu Pharmaceutical Co., Ltd. It details the terms and implications of the agreement, focusing on distribution and marketing rights for a pharmaceutical product. The document is relatively short (3881 characters) and does not contain financial statements, earnings data, or regulatory certifications. It is not an annual or interim report, nor a call transcript or audit report. The content is about a strategic alliance, which is a form of business cooperation but not a merger or acquisition filing. It is an announcement of a business development rather than a detailed investor presentation or management report. Given the nature and length, and that it is an announcement of a strategic cooperation, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-06-27 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.